BIO-TECHNE Corp
TECHAPI behind this page
TECH Q1 2026 request
Playground key active
/api/financials?ticker=TECH&year=2026&quarter=1
Pick an endpoint and run the request.Income Statement
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Revenue | 286,555 | 289,458 | -1.0% |
Show Product Lines breakouts |
|||
| Consumables | 231,601 | 230,845 | +0.3% |
| Instruments | 21,826 | 26,206 | -16.7% |
| Product and Services | 280,909 | 284,408 | -1.2% |
| Royalty | 5,646 | 5,050 | +11.8% |
| Service | 27,482 | 27,357 | +0.5% |
Show Business Segments breakouts |
|||
| Diagnostics and Spatial Biology · Operating Segments | 79,458 | 83,192 | -4.5% |
| Protein Sciences · Operating Segments | 202,188 | 204,535 | -1.1% |
Show Geography breakouts |
|||
| APAC, excluding Greater China | 19,147 | 18,122 | +5.7% |
| CN | 24,786 | 24,321 | +1.9% |
| EMEA, excluding United Kingdom | 65,128 | 59,063 | +10.3% |
| GB | 13,205 | 13,944 | -5.3% |
| Rest of World | 9,049 | 8,993 | +0.6% |
| US | 155,240 | 165,015 | -5.9% |
Show Consolidation Items breakouts |
|||
| Intersegment Elimination | -530 | -572 | +7.3% |
| Operating Segments | 281,646 | 287,727 | -2.1% |
| Cost of Revenue | 98,443 | 106,441 | -7.5% |
Show Business Segments breakouts |
|||
| Diagnostics and Spatial Biology · Operating Segments | 33,737 | 35,633 | -5.3% |
| Protein Sciences · Operating Segments | 50,518 | 52,498 | -3.8% |
| Gross Profit | 188,112 | 183,017 | +2.8% |
| Selling, General & Administrative | 116,213 | 119,161 | -2.5% |
Show Business Segments breakouts |
|||
| Diagnostics and Spatial Biology · Operating Segments | 27,851 | 33,518 | -16.9% |
| Protein Sciences · Operating Segments | 59,766 | 57,132 | +4.6% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | -2,433 | -1,586 | -53.4% |
| Research And Development Expense Excluding Acquired In Process Cost | 24,241 | 23,869 | +1.6% |
Show Business Segments breakouts |
|||
| Diagnostics and Spatial Biology · Operating Segments | 8,992 | 9,764 | -7.9% |
| Protein Sciences · Operating Segments | 14,191 | 14,364 | -1.2% |
| Operating Expenses | 140,454 | 143,030 | -1.8% |
| Operating Income | 47,658 | 39,987 | +19.2% |
Show Business Segments breakouts |
|||
| Diagnostics and Spatial Biology · Operating Segments | 8,878 | 4,277 | +107.6% |
| Protein Sciences · Operating Segments | 77,713 | 80,541 | -3.5% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 86,591 | 84,818 | +2.1% |
| Non-Operating Income (Expense) | 333 | 184 | +81.0% |
| Income Before Taxes | 47,991 | 40,171 | +19.5% |
| Income Tax Expense (Benefit) | 9,806 | 6,571 | +49.2% |
| Net Income | 38,185 | 33,600 | +13.6% |
| Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent | -2,850 | 21,256 | -113.4% |
| Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent | -1,665 | -3,027 | +45.0% |
| Other Comprehensive Income Loss Net Of Tax | -4,515 | 18,229 | -124.8% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | -4,515 | 18,229 | -124.8% |
| Comprehensive Income | 33,670 | 51,829 | -35.0% |
| EPS (Basic) | 0.25 | 0.21 | +19.0% |
| EPS (Diluted) | 0.24 | 0.21 | +14.3% |
| Wtd Avg Shares (Basic) | 155,464 | 158,531 | -1.9% |
| Wtd Avg Shares (Diluted) | 156,362 | 161,115 | -3.0% |
| Revenue | 286,555 | 289,458 | -1.0% |
| Interest Expense | -2,934 | -2,176 | -34.8% |
| Other Comprehensive Income (Q) | — | — | — |
Show Equity Components breakouts |
|||
| Accumulated Net Unrealized Investment Gain Loss | -1,665 | -3,027 | +45.0% |
| Accumulated Other Comprehensive Income | -4,515 | 18,229 | -124.8% |
| Accumulated Translation Adjustment | -2,850 | 21,256 | -113.4% |
| Net Income Loss Available To Common Stockholders Basic | 38,179 | 33,594 | +13.6% |
| Income Loss From Equity Method Investments | 294 | 374 | -21.4% |
Balance Sheet
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 144,962 | 187,540 | -22.7% |
| Accounts Receivable | 183,897 | 223,688 | -17.8% |
| Inventory | 203,188 | 185,041 | +9.8% |
| Other Assets Current | 77,460 | 42,839 | +80.8% |
| Total Current Assets | 609,507 | 648,567 | -6.0% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 240,334 | 253,939 | -5.4% |
| Operating Lease Right-of-Use Assets | 70,725 | — | — |
| Goodwill | 978,912 | — | — |
Show Business Segments breakouts |
|||
| Diagnostics and Spatial Biology | 554,111 | — | — |
| Protein Sciences | 424,801 | — | — |
| Other Non-Current Assets | 276,563 | 275,701 | +0.3% |
| Total Assets | 2,526,148 | 2,736,017 | -7.7% |
| Intangible Assets | 350,107 | — | — |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 350,107 | — | — |
| Current Liabilities | |||
| Accounts Payable | 30,157 | 31,559 | -4.4% |
| Employee Related Liabilities Current | 43,599 | 41,977 | +3.9% |
| Accrued Liabilities | 19,179 | 21,088 | -9.1% |
| Deferred Revenue (Current) | 30,445 | 26,614 | +14.4% |
| Accrued Income Taxes Current | 2,848 | 3,136 | -9.2% |
| Operating Lease Liability Current | 13,771 | — | — |
| Other Liabilities Current | 4,546 | 4,269 | +6.5% |
| Total Current Liabilities | 144,545 | 142,128 | +1.7% |
| Non-Current Liabilities | |||
| Deferred Tax Liabilities | 11,273 | — | — |
| Operating Lease Liabilities | 80,702 | — | — |
| Other Non-Current Liabilities | 23,814 | 19,789 | +20.3% |
| Other Liabilities | |||
| Long Term Debt And Capital Lease Obligations | 300,000 | 300,000 | 0.0% |
| Stockholders' Equity | |||
| Common Stock | 1,557 | 1,589 | -2.0% |
| Additional Paid In Capital Common Stock | 946,118 | 855,973 | +10.5% |
| Retained Earnings | 1,082,534 | 1,341,175 | -19.3% |
| Accumulated Other Comprehensive Income | -64,395 | -60,087 | -7.2% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 1,965,814 | 2,138,650 | -8.1% |
Show Equity Components breakouts |
|||
| Accumulated Net Unrealized Investment Gain Loss | 871 | 5,075 | -82.8% |
| Accumulated Other Comprehensive Income | -64,395 | -60,087 | -7.2% |
| Accumulated Translation Adjustment | -65,266 | -65,162 | -0.2% |
| Additional Paid In Capital | 946,118 | 855,973 | +10.5% |
| Common Stock | 1,557 | 1,589 | -2.0% |
| Retained Earnings | 1,082,534 | 1,341,175 | -19.3% |
| Total Liabilities & Equity | 2,526,148 | 2,736,017 | -7.7% |
Cash Flow Statement
| Metric | YTD Q1 2026 | YTD Q1 2025 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Net Income | 38,185 | 33,600 | +13.6% |
Show Equity Components breakouts |
|||
| Retained Earnings | 38,185 | 33,600 | +13.6% |
| Depreciation & Amortization | 24,340 | 28,137 | -13.5% |
| Deferred Income Taxes And Tax Credits | 5,275 | -5,340 | +198.8% |
| Stock-Based Compensation | 11,682 | 10,184 | +14.7% |
| Equity Method Investment Realized Gain Loss On Disposal | -294 | -374 | +21.4% |
| Unrealized Gain Loss On Investments | -2,054 | — | — |
| Noncash Portion Of Lease Expense | -912 | 445 | -304.9% |
| Recovery Of Assets Held For Sale | -6,789 | — | — |
Show Business Segments breakouts |
|||
| Exosome Diagnostics · Disposal Group Disposed Of By Sale Not Discontinued Operations | -6.8 | — | — |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | -6,789 | — | — |
| Other Operating Activities Cash Flow Statement | 1,001 | 935 | +7.1% |
| Increase Decrease In Accounts And Other Receivables | 22,392 | 21,563 | +3.8% |
| Change in Inventory | -14,002 | -2,805 | -399.2% |
| Increase Decrease In Prepaid Expense | 380 | -3,158 | +112.0% |
| Increase Decrease In Accounts Payable And Accrued Liabilities | -2,115 | -10,911 | +80.6% |
| Increase Decrease In Employee Related Liabilities | -22,101 | -8,246 | -168.0% |
| Increase Decrease In Accrued Income Taxes Payable | -27,403 | -6,180 | -343.4% |
| Net Cash from Operations | 27,585 | 63,889 | -56.8% |
| Deferred Income Taxes (Q) | — | — | — |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | 0.3 | 1.6 | -81.2% |
| Investing Activities | |||
| Capital Expenditures | -5,363 | -9,172 | +41.5% |
| Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital | 1,351 | 1,403 | -3.7% |
| Proceeds From Sale Of Property Held For Sale | 4,617 | — | — |
| Net Cash from Investing | 605 | -21,684 | +102.8% |
| Financing Activities | |||
| Payments Of Dividends Common Stock | -12,444 | -12,688 | +1.9% |
| Proceeds From Stock Options Exercised | 23,495 | 25,101 | -6.4% |
| Share Repurchases | -24 | — | — |
| Repayments Of Lines Of Credit | -46,000 | -19,000 | -142.1% |
| Tax Withholding for Share Compensation | -9,231 | -4,984 | -85.2% |
| Net Cash from Financing | -44,204 | -11,571 | -282.0% |
| Supplemental | |||
| Income Taxes Paid | 30,812 | 16,490 | +86.9% |
| Interest Paid | 4,822 | 5,205 | -7.4% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | -1,210 | 5,115 | -123.7% |
| Net Change in Cash | -17,224 | 35,749 | -148.2% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 144,962 | 187,540 | -22.7% |
Values in thousands USD. Source: SEC EDGAR 10-Q filing.